Amgen Debuts Oncology Biosimilars Bevacizumab And Trastuzumab In US

 
• By Dave Wallace

Amgen has launched its Kanjinti biosimilar version of trastuzumab in the US after a court refused Genentech’s request for an injunction. At the same time, Amgen has also introduced its Mvasi bevacizumab biosimilar. The launches represent Amgen’s first biosimilar introductions in the US.

Amgen
Amgen has launched two US biosimilars • Source: Shutterstock

Amgen has launched its Kanjinti (trastuzumab-anns) biosimilar rival to Genentech's Herceptin and its Mvasi (bevacizumab-awwb) biosimilar version of Genentech's Avastin in the US.

The launch of Kanjinti, the first marketed US trastuzumab biosimilar – which was only approved a month ago and marked the fifth biosimilar trastuzumab to be approved in the US (Also see "FDA Approves Amgen And Allergan’s Kanjinti Trastuzumab Biosimilar" - Generics Bulletin, 14 June, 2019

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business